COULD LOW-THC CANNABIS AND NON-THC CANNABINOIDS BE THE SECRET TO TREATING CANCER?
FARJANA AFRIN, MENGNA CHI, ANDREW L. EAMENS, RYAN J. DUCHATEL, ALICIA M. DOUGLAS, JENNIFER SCHNEIDER, CRAIG GEDYE, AMEHA S. WOLDU & MATTHREW D. DUN. CANCERS (BASEL). 2020 APR; 12(4): 825-1033.PUBLISHED ONLINE 2020 APR. 23 DOI: [10.3390/CANCERS12041033].
Pre-clinical studies documenting the anti-cancer effects of THC and its success in inhibiting cancer growth and spread have been on the rise. Clinical studies however are scarce, as the psychoactive effects of THC can limit its medicinal and clinical use. Could the non-psychoactive cannabinoids found in cannabis and low-THC hemp be the answer to treating cancer instead?
This ANTG funded review, in conjunction with HMRI, the Cancer Institute NSW and National Health and Medical Research Council, explores the emerging mechanisms of anti-cancer properties of hemp and non-THC cannabinoids such as CBD (Cannabidiol).
At ANTG, we are uniquely well-positioned to supply the domestic market and become the first medicinal cannabis company in Australia to export cannabis flower for commercial purposes to the EU. Interested in investing in medicinal cannabis? Read what sets ANTG apart.